A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 2, 2019

Primary Completion Date

September 3, 2024

Study Completion Date

September 3, 2024

Conditions
Granulosa Cell Ovarian CancerLow Grade Serous Ovarian/ Primary Peritoneal CancerEndometrioid Endometrial Cancer
Interventions
DRUG

Onapristone ER

50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.

DRUG

Onapristone ER + Anastrozole

Onapristone ER Patients will take 50 PO BID in the form of two 20 mg tablets and one 10 mg tablet taken with food and water twice daily. Patients will be prescribed anastrozole 1mg PO QD. Anastrozole will be taken once daily in the AM with patients morning dose of onapristone ER.

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11570

Memorial Sloan Kettering Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Context Therapeutics Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03909152 - A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone | Biotech Hunter | Biotech Hunter